biokine_amir

About Amir Caspi

This author has not yet filled in any details.
So far Amir Caspi has created 39 blog entries.

Biokine Announces Issuance of European Patent

Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 20th, 2015|Pre-Clinical Programs, Recent News|

Biokine Announces Issuance of Mexican Patent

Biokine Therapeutics Announces Issuance of Mexican Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 19th, 2015|Pre-Clinical Programs, Recent News|

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

Clinical trials in three additional indications for BL-8040 to be initiated in 2015
Development strategy presented today at BioLineRx investor meeting in New York

December 12th, 2014|Clinical Program BL8040, Recent News|

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis

December 8th, 2014|Clinical Program BL8040, Recent News|

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile

The amendment will include the testing of higher doses, resulting in an increase in the total study population to 70 patients. The changes were unanimously recommended by the Clinical Advisory Board.

November 3rd, 2014|Clinical Program BL8040, Recent News|

Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a Phase […]

September 17th, 2014|Clinical Program BL8040, Recent News|

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

The results from the phase 1 trial expected by end of 2014 or early 2015. BKT-140/BL-8040 is also in the midst of a Phase 2 trial for AML, with results expected in early 2015.

September 3rd, 2014|Clinical Program BL8040, Recent News|

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors (BKT130 Project).

August 5th, 2014|Pre-Clinical Programs|

Biokine Therapeutics Announces Issuance of Japanese Patent covering the composition and use of polypeptides

Biokine Therapeutics Announces Issuance of Japanese Patent covering the composition and use of polypeptides

July 2nd, 2014|Pre-Clinical Programs|

Patent issued in Japan covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of Japan Patent covering the composition and use of novel chemokine binding polypeptides
capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

July 1st, 2014|Pre-Clinical Programs, Recent News|